BACKGROUND: GSK's varicella vaccine contains human serum albumin (HSA) which is used to stabilize the virus and prevent immunogens from adhering to the injection vial walls. However, because HSA is derived from human blood, there is a theoretical risk that it might contain infectious agents which could be unsafe for humans. Given this concern, a study was undertaken to compare the immunogenicity and safety of a new formulation without HSA with the currently licensed varicella vaccine in the Czech Republic and Hungary. METHODS: Healthy children aged 11-21 months received two doses of the varicella vaccine either with or without HSA. Antibody titres against varicella-zoster virus (anti-VZV) were measured 42 days after each dose, using an immunofluorescence assay (IFA, cut-off = 4dilution(-1)) and enzyme linked immunosorbent assay (ELISA, cut-off = 25 mIU/ml). Solicited local symptoms were recorded during a 4-day post-vaccination follow-up period; solicited general and unsolicited symptoms were recorded during a 43-day post-vaccination follow-up period and serious adverse event (SAEs) were recorded throughout the study. RESULTS: Of 244 children (mean age = 15.2 months [SD = 3.2]) vaccinated in the study, 233 (vaccine without HSA N = 117; vaccine containing HSA N = 116) formed the according-to-protocol immunogenicity cohort. Observed seroconversion/seroresponse rates were >98 and 100 %, 42 days after doses 1 and 2, respectively. The rates were within the same range in both groups, irrespective of the testing assay. The varicella vaccine without HSA was non-inferior to the licensed vaccine in terms of anti-VZV antibody Geometric Mean Titre/Concentration ratio (1.12 [95 % CI:0.86-1.46] by IFA; 1.12 [95 % CI:0.93-1.33] by ELISA) approximately six weeks after the first dose of the 2-dose vaccination course. The incidence of solicited and unsolicited symptoms was similar after both vaccines; low-grade fever was numerically higher after the first dose of the varicella vaccine without HSA. Seven SAEs were reported, none of which were fatal or considered to be vaccine-related. CONCLUSIONS: The first dose of a new varicella vaccine without HSA was immunologically non-inferior to the licensed varicella vaccine. After two doses, both vaccines had acceptable safety profiles in children aged 11-21 months in the Czech Republic and Hungary. TRIAL REGISTRATION: NCT00568334 , registered on 5 December 2007 ( www.clinicaltrials.gov ).

Faculty of Military Health Sciences University of Defence Trebesska 1575 50001 Hradec Kralove Czech Republic

GSK Vaccines Avenue Fleming 20 B 1300 Wavre Belgium

Primary Care Paediatric Praxis No 8 Miskolc Hungary

Szent László Hospital Gyali Street 5 7 Budapest 1097 Hungary

Zobrazit více v PubMed

Lopez A, Schmid S, Bialek S: VPD Surveillance Manual: Varicella [http://www.cdc.gov/vaccines/pubs/surv-manual/chpt17-varicella.pdf]. Accessed 21 May, 2014.

Vaccines and Immunizations: Varicella [http://www.cdc.gov/vaccines/pubs/pinkbook/varicella.html]. Accessed 21 May, 2014.

Shapiro M, Kvern B, Watson P, Guenther L, McElhaney J, McGeer A. Update on herpes zoster vaccination: a family practitioner’s guide. Can Fam Physician. 2011;57:1127–31. PubMed PMC

Marin M, Güris D, Chaves SS, Schmid S, Seward JF, Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC) Prevention of varicella: recommendations of advisory committee on immunization practices (ACIP) MMRV Recomm Rep. 2007;56:1–40. PubMed

Aebi C, Fischer K, Gorgievski M, Matter L, Muhlemann K. Age-specific seroprevalence to varicella-zoster virus: study in Swiss children and analysis of European data. Vaccine. 2001;19:3097–103. doi: 10.1016/S0264-410X(01)00035-4. PubMed DOI

Gabutti G, Penna C, Rossi M, Salmaso S, Rota MC, Bella A, et al. The seroepidemiology of varicella in Italy. Epidemiol Infect. 2001;126:433–40. PubMed PMC

Kanra G, Tezcan S, Badur S, Turkish National Study Team Varicella seroprevalence in a random sample of the Turkish population. Vaccine. 2002;20:1425–8. doi: 10.1016/S0264-410X(01)00459-5. PubMed DOI

Schmitt HJ, Booy R, Weil-Olivier C, Van Damme P, Cohen R, Peltola H. Child vaccination policies in Europe: a report from the summits of independent european vaccination experts. Lancet Infect Dis. 2003;3:103–8. doi: 10.1016/S1473-3099(03)00519-X. PubMed DOI

Thiry N, Beutels P, Shkedy Z, Vranckx R, Vandermeulen C, Wielen MV, et al. The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium) Eur J Pediatr. 2002;161:588–93. doi: 10.1007/s00431-002-1053-2. PubMed DOI

Sengupta N, Booy R, Schmitt HJ, Peltola H, Van-Damme P, Schumacher RF, et al. Varicella vaccination in Europe: are we ready for a universal childhood program? Eur J Pediatr. 2008;167:47–55. doi: 10.1007/s00431-007-0424-0. PubMed DOI

Ciofi Degli Atti ML, Salmaso S, Bella A, Arigliani R, Gangemi M, Chiamenti G, et al. Pediatric sentinel surveillance of vaccine-preventable diseases in Italy. Pediatr Infect Dis J. 2002;21:763–8. doi: 10.1097/00006454-200208000-00013. PubMed DOI

Pinot De Moira A, Nardone A, ESEN2 Group Varicella Zoster Virus Vaccination Policies and Surveillance Strategies in Europe. Euro Surveill. 2005;10:43–4. PubMed

Gershon A, Takahashi M, Seward J. Varicella vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. 4. Philadelphia (PA): Saunders; 2004. pp. 783–825.

Skull SA, Wang EE. Varicella vaccination: a critical review of the evidence. Arch Dis Child. 2001;85:83–90. doi: 10.1136/adc.85.2.83. PubMed DOI PMC

Prymula R, Bergsaker MR, Esposito S, Gothefors L, Man S, Snegova N, et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet. 2014;383:1313–24. doi: 10.1016/S0140-6736(12)61461-5. PubMed DOI

World Health Organization The WHO position paper on varicella vaccines. Wkly Epidemiol Rec. 1998;73:241–8. PubMed

Macartney KK, Burgess MA. Varicella vaccination in Australia and New Zealand. J Infect Dis. 2008;197(Suppl 2):S191–5. doi: 10.1086/522157. PubMed DOI

National Advisory Committee on Immunization National Advisory Committee on Immunization (NACI) update on varicella. Can Commun Dis Rep. 2004;30:1–26. PubMed

Childhood immunization calendar, Greece [http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx]. Accessed 9 May, 2014.

Sadzot-Delvaux C, Rentier B, Wutzler P, Asano Y, Suga S, Yoshikawa T, et al. Varicella vaccination in Japan, South Korea and Europe. J Infect Dis. 2008;197:185–90. doi: 10.1086/522163. PubMed DOI

Quian J, Ruttimann R, Romero C, Dall’orso P, Cerisola A, Breuer T, et al. Impact of universal varicella vaccination of one year-olds in Uruguay: 1997–2005. Arch Dis Child. 2008;93:845–50. doi: 10.1136/adc.2007.126243. PubMed DOI PMC

WHO vaccine preventable disease monitoring system: Immunization schedules by antigen, selection centre [http://apps.who.int/immunization_monitoring/globalsummary/schedules]. Accessed 9 May, 2014.

Liao SL, Huang T, Huang YC, Jiang DD. Survey of the status of self-paid varicella vaccination among children one to six years of age in Taiwan. J Microbiol Immunol Infect. 2007;40:112–5. PubMed

Reynolds MA, Watson BM, Plott-Adams KK, Jumaan AO, Galil K, Maupin TJ, et al. Epidemiology of varicella hospitalizations in the United States, 1995–2005. J Infect Dis. 2008;197:120–6. doi: 10.1086/522146. PubMed DOI

Kreth HW, Lee BW, Kosuwon P, Salazar J, Gloriani-Barzaga N, Bock HL, et al. Sixteen years of global experience with the first refrigerator-stable varicella vaccine (Varilrix) BioDrugs. 2008;22:387–402. doi: 10.2165/0063030-200822060-00005. PubMed DOI

Offit PA, Jew RK. Addressing parents’ concerns: do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatr. 2003;112:1394–7. doi: 10.1542/peds.112.6.1394. PubMed DOI

EMA: The European Agency for the Evaluation of Medicinal Products: Note for Guidance on Plasma-Derived Medicinal Products. 2001. [http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003613.pdf] Accessed 7 October, 2015.

Lau YL, Vessey SJ, Chan IS, Lee TL, Huang LM, Lee CY, et al. A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX™ in healthy children. Vacc. 2002;20(23–24):2942–9. doi: 10.1016/S0264-410X(02)00245-1. PubMed DOI

Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, et al. Immunogenicity and Safety Assessments After One and Two Doses of a Refrigerator-Stable Tetravalent Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children During the Second Year of Life. Pediatr Infect Dis J. 2008;27(8):724–30. doi: 10.1097/INF.0b013e318170bb22. PubMed DOI

Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of binomial. Biometrika. 1934;26:404–13. doi: 10.1093/biomet/26.4.404. DOI

Newcombe RG. Interval estimation for the difference between independent proportions: Comparison of eleven methods. Statist Med. 1998;17:873–90. doi: 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I. PubMed DOI

EMEA–CHMP. EMEA–CHMP: Position Statement on Creutzfeldt–Jakob Disease and Plasma-derived and Urine-derived Medicinal Products (2004). [http://www.ema.europa.eu/docs/en_GB/document_library/Position_statement/2011/06/WC500108071.pdf]. Accessed 9 May, 2014.

Deedler AM, Kornelis D. A comparison of the IFA and the ELISA for the demonstration of antibodies against Schistosome gut-associated polysaccharide antigens in Schistosomiasis. Parasite Res. 1980;64:65–75. PubMed

Yahara Y, Okhubo Y, Kariwa H, Takashima I. Evaluation of enzyme-linked immunosorbent assay (ELISA) and immunofluorescent antibody (IFA) test for the detection of porcine reproductive and respiratory syndrome virus (PRRSV) antibody in pigs from conventional farms. J Vet Med Science. 2002;64:583–8. doi: 10.1292/jvms.64.583. PubMed DOI

Gillet Y, Steri GC, Behre U, Arsène JP, Lanse X, Helm K, et al. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months–2 years or 2–6 years primed with measles-mumps-rubella (MMR) vaccine. Vaccine. 2009;27:446–53. doi: 10.1016/j.vaccine.2008.10.064. PubMed DOI

Hadinegoro SR, Hindra IS, Han HH, Gatchalian S, Bock HL. Reactogenicity and immunogenicity of a live-attenuated refrigerator-stable varicella vaccine (OKA strain) in healthy seronegative children age 10 months to 12 years. Southeast Asian J Trop Med Public Health. 2009;40:991. PubMed

Zobrazit více v PubMed

ClinicalTrials.gov
NCT00568334